EP4021912A4 - Prodrugs of the tyrosine kinase inhibitor for treating cancer - Google Patents
Prodrugs of the tyrosine kinase inhibitor for treating cancer Download PDFInfo
- Publication number
- EP4021912A4 EP4021912A4 EP20857153.9A EP20857153A EP4021912A4 EP 4021912 A4 EP4021912 A4 EP 4021912A4 EP 20857153 A EP20857153 A EP 20857153A EP 4021912 A4 EP4021912 A4 EP 4021912A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- prodrugs
- tyrosine kinase
- kinase inhibitor
- treating cancer
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910817505.XA CN112442009B (en) | 2019-08-30 | 2019-08-30 | Deuterated compounds and their use for treating cancer |
| CN201910818779.0A CN112442011B (en) | 2019-08-30 | 2019-08-30 | Prodrug compound and application thereof in treating cancers |
| CN201910818675.XA CN112442010B (en) | 2019-08-30 | 2019-08-30 | Prodrug compounds and application thereof in treating cancers |
| US202062994364P | 2020-03-25 | 2020-03-25 | |
| PCT/CA2020/051177 WO2021035360A1 (en) | 2019-08-30 | 2020-08-28 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4021912A1 EP4021912A1 (en) | 2022-07-06 |
| EP4021912A4 true EP4021912A4 (en) | 2023-08-23 |
Family
ID=74684795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20857153.9A Pending EP4021912A4 (en) | 2019-08-30 | 2020-08-28 | Prodrugs of the tyrosine kinase inhibitor for treating cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4021912A4 (en) |
| AU (1) | AU2020338490A1 (en) |
| CA (1) | CA3147801A1 (en) |
| IL (1) | IL290798A (en) |
| WO (1) | WO2021035360A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106317017A (en) * | 2015-07-10 | 2017-01-11 | 李建成 | Novel compound used for treating ophthalmic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20010306A1 (en) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE |
| CN106336397A (en) * | 2015-07-07 | 2017-01-18 | 郭明山 | Novel compound for treating ophthalmic diseases |
| CN106478596A (en) * | 2015-08-25 | 2017-03-08 | 李建成 | A kind of noval chemical compound as treatment ophthalmic diseasess |
| CA3096963A1 (en) * | 2018-04-13 | 2019-10-17 | Hinova Pharmaceuticals Inc. | A new method for synthesis of deuterated amide and deuterated sulfonamide |
-
2020
- 2020-08-28 WO PCT/CA2020/051177 patent/WO2021035360A1/en unknown
- 2020-08-28 AU AU2020338490A patent/AU2020338490A1/en active Pending
- 2020-08-28 CA CA3147801A patent/CA3147801A1/en active Pending
- 2020-08-28 EP EP20857153.9A patent/EP4021912A4/en active Pending
-
2022
- 2022-02-22 IL IL290798A patent/IL290798A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106317017A (en) * | 2015-07-10 | 2017-01-11 | 李建成 | Novel compound used for treating ophthalmic diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| IL290798A (en) | 2022-04-01 |
| WO2021035360A1 (en) | 2021-03-04 |
| AU2020338490A1 (en) | 2022-03-17 |
| CA3147801A1 (en) | 2021-03-04 |
| EP4021912A1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3781564A4 (en) | Compounds for the treatment of cancer | |
| EP3758706A4 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
| EP4079735A4 (en) | Compound for inhibiting and inducing degradation of egfr kinase | |
| EP3804707A4 (en) | Kinase inhibitor | |
| EP4085053A4 (en) | Treatment of cancer with cdk12/13 inhibitors | |
| IL288522A (en) | Egfr inhibitor for the treatment of cancer | |
| EP3500257A4 (en) | Kinase inhibitor compounds, compositions, and methods of treating cancer | |
| EP3781584A4 (en) | 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer | |
| EP3927700A4 (en) | Kinase inhibitors | |
| IL286727A (en) | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma | |
| EP3892282A4 (en) | Combination for treating cancer | |
| EP3956035A4 (en) | Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations | |
| EP3787625A4 (en) | Methods of treating cancer | |
| EP4081527A4 (en) | The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer | |
| EP3843773A4 (en) | Inhibition of rip kinases for treating neurodegenerative disorders | |
| EP3630080A4 (en) | Use of ezh2 inhibitors for treating cancer | |
| EP3966208A4 (en) | Compounds and methods for treating cancer | |
| EP3781215A4 (en) | Methods of treating cancer | |
| EP3962919A4 (en) | Compounds for treating cancer | |
| EP3984553A4 (en) | Composition for preventing or treating cancer | |
| EP3893882A4 (en) | Cxcr7 inhibitors for the treatment of cancer | |
| EP3852816A4 (en) | Methods of treating cancer | |
| EP3774799C0 (en) | Nek6 kinase inhibitors useful for the treatment of solid tumors | |
| EP4021912A4 (en) | Prodrugs of the tyrosine kinase inhibitor for treating cancer | |
| EP3923947A4 (en) | Fgfr inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220322 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20230725 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 405/12 20060101ALI20230719BHEP Ipc: C07D 401/14 20060101ALI20230719BHEP Ipc: C07D 401/06 20060101ALI20230719BHEP Ipc: A61P 35/00 20060101ALI20230719BHEP Ipc: A61K 31/675 20060101ALI20230719BHEP Ipc: A61K 31/4439 20060101ALI20230719BHEP Ipc: C07F 9/6558 20060101AFI20230719BHEP |